Claudication
Methodology & AI Transparency ⓘ
Claudication Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under High Blood Pressure & Vascular Health diagnostic criteria (I73.9), workup for Claudication integrates 24-hour ambulatory blood in Claudication (I73.9: pressure monitoring) with evidence-graded therapy tailored to Serum Creatinine & in Claudication (I73.9: Potassium) response.
- 2 Real-world patient consensus: Mapped to High Blood Pressure & Vascular Health under ICD-10-CM I73.9 for Claudication clinical workups.
- 3 Typical cash cost range: Primary evaluation for Claudication incorporates 24-hour ambulatory blood in Claudication (I73.9: pressure monitoring) and symptom diary review.
- 4 Top reported side effects / signs: Key Blood Pressure biomarkers for Claudication (I73.9): Serum Creatinine & in Claudication (I73.9: Potassium) & Urine Albumin-to-Creatinine Ratio [Claudication I73.9] (< 15 mg/g (I73.9)).
Ask our AI Specialists anything about Claudication
What Is Claudication?
Under High Blood Pressure & Vascular Health diagnostic criteria (I73.9), workup for Claudication integrates 24-hour ambulatory blood in Claudication (I73.9: pressure monitoring) with evidence-graded therapy tailored to Serum Creatinine & in Claudication (I73.9: Potassium) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Claudication (I73.9, Blood Pressure) reflects venous valve incompetence [Claudication I73.9]. longitudinal control is benchmarked via Serum Creatinine & in Claudication (I73.9: Potassium).
Common Symptoms & Clinical Signs
- • Presentation of Claudication (I73.9): morning occipital headache, in Claudication (I73.9: pulsatile tinnitus, or)
- • Secondary Claudication clinical sign: calf cramping or in Claudication (I73.9: claudication triggered by)
- • Symptom flares in Claudication correlating with Serum Creatinine & in Claudication (I73.9: Potassium) deviation outside K+ 4.0 – 4.8 mEq/L (I73.9)
- • Functional blood pressure impact requiring 24-hour ambulatory blood in Claudication (I73.9: pressure monitoring) evaluation (I73.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Claudication Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I73.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Creatinine & in Claudication (I73.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Claudication I73.9] | < 15 mg/g (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Claudication (I73.9: Pressure) | < 120/75 mmHg (I73.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Claudication
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Pentoxifylline Trental • RxCUI 312301 | Blood Viscosity Reducer | 82% | $0.2250 | $ 17.61 /mo |
| Cilostazol Pletal • RxCUI 242461 | Phosphodiesterase 3 Inhibitor | 76% | $0.1250 | $ 7.18 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Claudication)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of Actovegin in the treatment of intermittent claudication:: What a 366-Participant Study Found The results of this 12-week course of Actovegin demonstrated its superiority over placebo in the increase in ICD and ACD at weeks 2, 12 and 24 from the start of treatment. International angiology : a journal of the International Union of Angiology • 2022-10-15 • Phase III Randomized Trial | N = 366 | 93/100 | PMID 36264097 ↗ |
| New Insights on Semaglutide and walking capacity in people with symptomatic peripheral artery: What a 396-Participant Study Found Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. Lancet (London, England) • 2025-05-03 • Phase III Randomized Trial | N = 396 | 93/100 | PMID 40169145 ↗ |
| New Insights on Clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after: What a 221-Participant Study Found Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings. Journal of neurosurgery • 2022-12-01 • Phase III Randomized Trial | N = 221 | 88/100 | PMID 35364589 ↗ |
| Can This Approach Help? Inside the Latest Research on Valsartan blood-pressure-lowering Long-term Use Evaluation (VALUE) trial of heart A unique feature of VALUE is the assessment of the predictive power of this heart and blood vessel risk factor scale in a large population of treated hypertensive patients. Blood pressure • 1998-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 9758088 ↗ |
| Can This Approach Help? Inside the Latest Research on Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in REVEAL Lite 2 can monitor PAH M/M risk and facilitate treatment optimization. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39222737 ↗ |
Claudication Patient Community & “People Like Me” Threads
Filter Claudication community threads and patient logs by age, biological sex, dosage, and treatment duration.